Inhaled ergotamine for migraine: phase III results


MAP0004, a novel inhaled dihydroergotamine, is effective in the acute management of migraine, according to the results of the phase III FREEDOM-301 study (Aurora et al. Headache 2011; 51:507-517).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page